Imugene Limited (IMU.AX)
- Previous Close
0.0830 - Open
0.0820 - Bid 0.0830 x 102397000
- Ask 0.0800 x 716752400
- Day's Range
0.0770 - 0.0830 - 52 Week Range
0.0390 - 0.1500 - Volume
17,065,283 - Avg. Volume
15,867,325 - Market Cap (intraday)
591.007M - Beta (5Y Monthly) 3.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.35
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
www.imugene.comRecent News: IMU.AX
Performance Overview: IMU.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMU.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMU.AX
Valuation Measures
Market Cap
591.01M
Enterprise Value
438.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.15%
Return on Equity (ttm)
-44.37%
Revenue (ttm)
15.03M
Net Income Avi to Common (ttm)
-89.24M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
139.39M
Total Debt/Equity (mrq)
3.33%
Levered Free Cash Flow (ttm)
-46.52M
Research Analysis: IMU.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: IMU.AX
IMU.AX does not have Company Insights